Medtronic Reports Strong Q1 FY27 Financial Results

GALWAY, Ireland, Sept. 1, 2026, Medtronic plc, a global leader in healthcare technology, reported robust financial results for its first quarter of fiscal year 2027 (Q1 FY27), which ended July 31, 2026. The company's performance across key business segments and its strategic investments underscore its commitment to long-term growth.

Financial Performance

Medtronic reported a Q1 worldwide revenue of $9.756 billion, marking a 13.7% increase from the previous year, both on a reported and organic basis. The organic growth, which excludes certain divestitures and acquisitions, was in line with the company's expectations. The company noted an estimated $570 million benefit from an extra fiscal week in the quarter, which contributed to the strong revenue numbers.

The company's cardiovascular portfolio showed the most significant growth, increasing 18.9% on an organic basis, with particular strength in Cardiac Rhythm Management and Cardiac Ablation Solutions. Neuroscience and Medical Surgical segments also performed well, growing 9.3% and 10.2% respectively. The diabetes business saw a 16.9% increase in revenue.

Strategic Initiatives and Investments

Medtronic announced several strategic initiatives aimed at driving future growth. The company expanded the CE Mark indication for the Affera™ Mapping and Ablation System and Sphere-9™ Catheter for the treatment of ventricular arrhythmias. Additionally, Medtronic made a strategic investment in Pi-Cardia, a pioneer in leaflet modification technology, to further enhance its cardiovascular portfolio.

The company also announced a partnership with Cornerstone Robotics to expand global access to robotic-assisted surgery. Medtronic received FDA clearance for the next generation computing platform, Touch Surgery™ Aide. Furthermore, the company completed the acquisitions of Scientia Vascular and SPR Therapeutics, Inc., bolstering its portfolio and pipeline.

Earnings and Guidance

Medtronic's Q1 GAAP operating profit and operating margin stood at $1.764 billion and 18.1% respectively, with non-GAAP figures of $2.316 billion and 23.7%. The company reported GAAP net income of $1.470 billion and diluted earnings per share (EPS) of $1.14, both up significantly from the previous year. Non-GAAP net income and diluted EPS were $1.860 billion and $1.45, respectively.

In light of the strong performance, Medtronic raised its fiscal 2027 guidance. The company now projects organic revenue growth of 7.25% to 7.75%, up from the previous guidance of 6.75% to 7.25%. Diluted non-GAAP EPS guidance was raised to the range of $5.94 to $6.00, from the prior $5.90 to $6.00.

Executive Commentary

Geoff Martha, Medtronic's chairman and CEO, expressed confidence in the company's future. "We are off to a strong start in fiscal 2027," said Martha. "The breadth of performance across our businesses, combined with the increasing contributions from newer growth platforms, gives us confidence in the opportunities ahead."

Thierry Piéton, Medtronic's chief financial officer, added, "The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance."

Forward-Looking Statements

Medtronic cautioned that forward-looking statements in this release are subject to risks and uncertainties. The company noted that competitive factors, regulatory challenges, and economic conditions could impact its future performance.

Accessing More Information

Medtronic's commitment to innovation and its focus on addressing critical health challenges continue to drive its strategic direction and growth potential. With a strong Q1 performance and a robust pipeline of initiatives, the company is well-positioned for continued success in the global healthcare technology sector.

About Medtronic

Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company dedicated to alleviating pain, restoring health, and extending life through innovative solutions. Follow Medtronic on LinkedIn for the latest updates.

Forward-Looking Statements and Non-GAAP Financial Measures, -